Securities notice · Vesalius Longevity Labs is not yet a reporting issuer. The proposed reverse takeover transaction is subject to regulatory and shareholder approvals. Nothing on this site constitutes an offer to sell or solicitation to buy securities.
Financial reports.
Periodic financial statements and management's discussion & analysis (MD&A), by quarter, as they are filed on SEDAR+.
Reports, by quarter.
Quarterly financial statements and management's discussion & analysis (MD&A). Each document is posted here following its filing on SEDAR+.
Definitive source
Open SEDAR+Periodic and material filings related to the reverse takeover transaction and the resulting issuer are filed on SEDAR+, which remains the definitive source for all regulatory disclosure.